Principal Financial Group Inc. Has $67.46 Million Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Principal Financial Group Inc. lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,745,818 shares of the specialty pharmaceutical company's stock after acquiring an additional 64,958 shares during the period. Principal Financial Group Inc. owned 5.41% of Collegium Pharmaceutical worth $67,459,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in COLL. Foundry Partners LLC acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $492,000. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $757,000. Squarepoint Ops LLC boosted its stake in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company's stock worth $3,553,000 after purchasing an additional 72,874 shares during the period. Renaissance Technologies LLC lifted its position in Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company's stock worth $49,314,000 after acquiring an additional 113,300 shares during the period. Finally, BOKF NA acquired a new stake in Collegium Pharmaceutical in the second quarter valued at about $490,000.

Wall Street Analyst Weigh In

COLL has been the subject of several recent research reports. StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, HC Wainwright raised their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus price target of $42.60.

Collegium Pharmaceutical Stock Performance

COLL traded down $0.74 on Friday, hitting $29.70. 1,378,424 shares of the stock traded hands, compared to its average volume of 451,256. The firm has a market capitalization of $957.83 million, a PE ratio of 12.80 and a beta of 0.80. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The business has a fifty day moving average price of $32.48 and a two-hundred day moving average price of $34.32. Collegium Pharmaceutical, Inc. has a 52 week low of $28.97 and a 52 week high of $42.29.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.